Literature DB >> 9652997

Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone.

N Gitlin1, N L Julie, C L Spurr, K N Lim, H M Juarbe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9652997     DOI： 10.7326/0003-4819-129-1-199807010-00008

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  26 in total

1.  Severe but reversible hepatitis induced by troglitazone.

Authors:  T Schiano; K Dolehide; J Hart; A L Baker
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

Review 2.  The glitazones: proceed with caution.

Authors:  D Krische
Journal:  West J Med       Date:  2000-07

Review 3.  Modern pharmacotherapies for type 2 diabetes mellitus.

Authors:  S H Hsia
Journal:  J Natl Med Assoc       Date:  2001-09       Impact factor: 1.798

4.  Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells.

Authors:  Douglas M Frederick; Erina Y Jacinto; Niti N Patel; Thomas H Rushmore; Ruy Tchao; Peter J Harvison
Journal:  Toxicol In Vitro       Date:  2011-09-22       Impact factor: 3.500

5.  First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

Authors:  Constadina Panagiotopoulos; Rebecca Ronsley; Dean Elbe; Jana Davidson; Derryck H Smith
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-05

Review 6.  Important elements for the diagnosis of drug-induced liver injury.

Authors:  Vijay K Agarwal; John G McHutchison; Jay H Hoofnagle
Journal:  Clin Gastroenterol Hepatol       Date:  2010-02-17       Impact factor: 11.382

Review 7.  The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.

Authors:  N van Leeuwen; J J Swen; H-J Guchelaar; L M 't Hart
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

8.  Type 2 diabetes, thiazolidinediones, and cardiovascular risk.

Authors:  Clare Taylor; F D Richard Hobbs
Journal:  Br J Gen Pract       Date:  2009-07       Impact factor: 5.386

9.  Effect of gender, dose, and time on 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT)-induced hepatotoxicity in Fischer 344 rats.

Authors:  N N Patel; C M Crincoli; E L Kennedy; D M Frederick; R Tchao; P J Harvison
Journal:  Xenobiotica       Date:  2008-04       Impact factor: 1.908

10.  Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone.

Authors:  Herbert L Bonkovsky; Riad Azar; Steven Bird; Gyongyi Szabo; Barbara Banner
Journal:  Dig Dis Sci       Date:  2002-07       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.